The Future of Bipolar Disorder Treatment With Psychedelics and Neuromodulation

Published 2024-07-30
Drs Trisha Suppes and Scott T. Aaronson discuss rapid-acting therapies for bipolar disorder and the future of psychedelics and neuromodulation in its treatment.


Relevant disclosures can be found with the episode show notes on Medscape www.medscape.com/viewarticle/999802. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.


Resources


Bipolar Disorder emedicine.medscape.com/article/286342-overview


The Effects of Vagus Nerve Stimulation on the Course and Outcomes of Patients With Bipolar Disorder in a Treatment-Resistant Depressive Episode: A 5-Year Prospective Registry pubmed.ncbi.nlm.nih.gov/32358769/


A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality pubmed.ncbi.nlm.nih.gov/28359201/


c-Fos and pERK, Which Is a Better Marker for Neuronal Activation and Central Sensitization After Noxious Stimulation and Tissue Injury? pubmed.ncbi.nlm.nih.gov/19898681/


Repetitive Transcranial Magnetic Stimulation in the Treatment of Bipolar Disorder pubmed.ncbi.nlm.nih.gov/33282175/


Efficacy of Active vs Sham Intermittent Theta Burst Transcranial Magnetic Stimulation for Patients With Bipolar Depression: A Randomized Clinical Trial pubmed.ncbi.nlm.nih.gov/33710288/


A Retrospective Analysis of Bipolar Depression Treated With Transcranial Magnetic Stimulation pubmed.ncbi.nlm.nih.gov/33169946/


When to Hold and When to Fold: Early Prediction of Nonresponse to Transcranial Magnetic Stimulation in Major Depressive Disorder pubmed.ncbi.nlm.nih.gov/38458381/


Dosing Transcranial Magnetic Stimulation in Major Depressive Disorder: Relations Between Number of Treatment Sessions and Effectiveness in a Large Patient Registry pubmed.ncbi.nlm.nih.gov/37827360/


Sequenced Treatment Alternatives to Relieve Depression (STAR*D): Rationale and Design pubmed.ncbi.nlm.nih.gov/15061154/


Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Controlled Trial pubmed.ncbi.nlm.nih.gov/38055270/